[go: up one dir, main page]

MX2009010164A - Method for treating cb2 receptor mediated pain. - Google Patents

Method for treating cb2 receptor mediated pain.

Info

Publication number
MX2009010164A
MX2009010164A MX2009010164A MX2009010164A MX2009010164A MX 2009010164 A MX2009010164 A MX 2009010164A MX 2009010164 A MX2009010164 A MX 2009010164A MX 2009010164 A MX2009010164 A MX 2009010164A MX 2009010164 A MX2009010164 A MX 2009010164A
Authority
MX
Mexico
Prior art keywords
treating
receptor mediated
mediated pain
subject
pain
Prior art date
Application number
MX2009010164A
Other languages
Spanish (es)
Inventor
Christopher M Flores
Mark J Macielag
Mingde Xia
Kevin Paul Pavlick
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010164(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009010164A publication Critical patent/MX2009010164A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to a method for treating, ameliorating or preventing CB2 receptor mediated pain in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I): or a form thereof, wherein X1R1, X2R2, X3R3, X4R4 and X5R5 are as defined herein.
MX2009010164A 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain. MX2009010164A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89601707P 2007-03-21 2007-03-21
PCT/US2008/055102 WO2008115672A1 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Publications (1)

Publication Number Publication Date
MX2009010164A true MX2009010164A (en) 2009-10-12

Family

ID=39766330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010164A MX2009010164A (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain.

Country Status (13)

Country Link
EP (1) EP2139327A4 (en)
JP (1) JP2010522182A (en)
KR (1) KR20090120500A (en)
CN (1) CN101677555A (en)
AR (1) AR065801A1 (en)
AU (1) AU2008229265A1 (en)
CA (1) CA2681384A1 (en)
CL (1) CL2008000817A1 (en)
MX (1) MX2009010164A (en)
PE (1) PE20090551A1 (en)
TW (1) TW200904414A (en)
UY (1) UY30974A1 (en)
WO (1) WO2008115672A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
IN2014MN00226A (en) 2011-07-05 2015-09-25 Lupin Ltd

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551952A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
MXPA06011017A (en) * 2004-03-24 2007-03-21 Johnson & Johnson Tetrahydro-indazole cannabinoid modulators.
FR2875230A1 (en) * 2004-09-13 2006-03-17 Sanofi Aventis Sa CONDENSED PYRAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
US7851498B2 (en) * 2005-09-23 2010-12-14 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators

Also Published As

Publication number Publication date
KR20090120500A (en) 2009-11-24
CA2681384A1 (en) 2008-09-25
EP2139327A4 (en) 2011-06-15
JP2010522182A (en) 2010-07-01
WO2008115672A1 (en) 2008-09-25
AU2008229265A1 (en) 2008-09-25
CN101677555A (en) 2010-03-24
EP2139327A1 (en) 2010-01-06
TW200904414A (en) 2009-02-01
UY30974A1 (en) 2008-09-30
PE20090551A1 (en) 2009-05-16
AR065801A1 (en) 2009-07-01
CL2008000817A1 (en) 2008-09-26

Similar Documents

Publication Publication Date Title
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MX2009005649A (en) Treatment for multiple myeloma.
EA201300860A1 (en) CRYSTALLINE TRIPEPTIDE EPOXYKETON-PROTEASE INHIBITORS
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2009013353A (en) Telomerase activating compounds and methods of use thereof.
MY158994A (en) Ampk modulators
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
MX2009006195A (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use.
IN2012DN01233A (en)
TW200744586A (en) Therapeutic compounds
GEP20166443B (en) Heterocyclic compound and use thereof
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
MA32544B1 (en) Derivatives of pyridino pyridinone - their preparation and application in treatment
NZ601350A (en) Method of treating arthritis
UA107562C2 (en) METHOD OF TREATMENT OF PSORIASIS
BRPI0720050A2 (en) 6-OXO-1,6-DIIDROPYRIMIDIN-2-ILAS IN THE TREATMENT OF PROLIFERATIVE DISEASES
TNSN08506A1 (en) Substituted carboxamides
BR112012006070A2 (en) compositions and methods for treating seizure disorders.
MX2010003071A (en) Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain.
MX2012001449A (en) Inhibitors of jnk.
MX2009010164A (en) Method for treating cb2 receptor mediated pain.
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.